Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.4% – Still a Buy?

Eli Lilly and Company (NYSE:LLY)’s stock price rose 1.4% on Thursday . The company traded as high as $1,189.07 and last traded at $1,172.50. 2,781,459 shares changed hands during trading, a decline of 13% from the average daily volume of 3,185,476 shares. The stock had previously closed at $1,156.63.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s AtaiBeckley acquisition adds a promising late-stage mental health pipeline, potentially broadening its growth opportunities beyond obesity and diabetes. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Investors are also encouraged by ongoing pipeline momentum, including new clinical-trial updates across obesity, addiction, and other programs that reinforce Lilly’s R&D depth. Eli Lilly Expands Obesity Pipeline With New Phase 1 Eloralintide Trial
• Neutral Sentiment: Analysts are highlighting continued momentum in Lilly’s GLP-1 and amylin efforts, which supports sentiment but does not change near-term fundamentals on its own. Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says
• Negative Sentiment: Some commentary says the AtaiBeckley deal is a long-dated bet, since pivotal data for the lead psychedelic program may not arrive until 2029, creating execution and regulatory risk. Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
• Negative Sentiment: There is also concern that Lilly may be paying up for a speculative asset, which could weigh on returns if the acquired programs fail to deliver. Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion

Analyst Ratings Changes

LLY has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. UBS Group lifted their target price on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a research note on Monday. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Finally, Berenberg Bank increased their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company Price Performance

The stock has a market capitalization of $1.10 trillion, a P/E ratio of 41.65, a PEG ratio of 1.41 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business has a fifty day simple moving average of $1,110.32 and a 200-day simple moving average of $1,035.14.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.5 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Institutional Trading of Eli Lilly and Company

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Spire Wealth Management raised its stake in Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after acquiring an additional 592 shares during the period. Coldstream Capital Management Inc. boosted its position in Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after purchasing an additional 8,659 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock worth $33,471,000 after purchasing an additional 7,338 shares in the last quarter. Iams Wealth Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $754,000. Finally, Danske Bank A S bought a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $512,022,000. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.